All News
No Increased Risk of Colitis Flares in Secukinumab Trials
No increased incidence of inflammatory bowel disease has been seen among patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis treated with secukinumab (Cosentyx) in the clinical trial programs for this interleukin (IL)-17A inhibitor, a researcher reported here.
Read Article
EULAR: Tofacitinib Effective in Ankylosing Spondylitis
Desiree van der Heidje, MD, PhD presented the results of a 16-week, phase II, dose-ranging study of tofacitinib (TOFA) in patients with active ankylosing spondylitis.
Read Article
IL-23 Inhibitor Effective in Crohn's Disease
Selective IL-23 inhibition has been touted to be the next great advance in the treatment of inflammatory bowel and psoriatic disease.
Read Article
TB Management Questions
The following is a compilation of several frequently asked questions regarding tuberculosis (TB) testing or treatment in patients on a TNF inhibitor (TNFi) or other biologic agents.
Read Article
Secukinumab Improves Patient-Reported Outcomes in Psoriatic Arthritis (FUTURE 1)
Secukinumab (Cosentyx) has recently been approved for use in ankylosing spondylitis and psoriatic arthritis; the latter largely based on the FUTURE 2 and the just reported FUTURE 1 clinical trial. FUTURE 1 demonstrates the efficacy and safety of secukinumab, with inital weekly intravenous loading, given monthly as a subcutaneous injection.
Read Article
Moderate Alcohol Intake While on Methotrexate Appears Prudent
Research presented at the annual British Society for Rheumatology conference revealed that rheumatoid arthritis patients who drink moderately while taking methotrexate appear to be at no greater risk for liver damage than nondrinkers.
Read Article
The RheumNow Week in Review – 6 May 2016
Watch Dr. Cush discuss the highlights from this week on RheumNow.com.
Read Article
Methotrexate Yields No Added Benefit in Etanercept Treated Psoriatic Arthritis Patients
Despite a paucity of clinical trial proof, methotrexate is often advocated or mandated to treat psoriatic arthritis. A recent comparison of clinical trials outcomes fails to show any added value when MTX is given to PsA patients taking etanercept.
Read Article
Simple Referral Rule May Lead to Earlier Referral and Diagnosis of Axial Spondyloarthritis
Early referral and diagnosis remains a challenge for many who care for patients with musculoskeletal complaints. This is especially so in those with chronic low back pain (LBP) and the minority who will have ankylosing spondylitis or axial spondyloarthritis.
Read Article
Biosimilar Switching Shows Favorable Interchangeability
Interchangeability is a major issue that will determine the success of biosimilars.
Read Article
Low Adherence to Biologics in Psoriasis Patients
Doshi and colleagues have conducted a retrospective claims analysis (2009 through 2012) of psoriasis patients on Medicare to examine the use and adherence to those initiating treatment with either infliximab, etanercept, adalimumab, or ustekinumab.
Read Article
Vaccine Success is Limited in Rheumatoid Arthritis
Numerous guidelines (ACR, ACIP/CDC, ATS, NICE) all call for timely vaccinations in patients with rheumatoid arthritis (RA) and those receiving immunosuppressives or biologics.
Read Article
Does Psoriasis Increase Risk of Abdominal Aneurysm?
Danish researchers studied a cohort of 59,423 mild psoriasis and 11,566 severe psoriasis patients over a 14 year period, and found 240 and 50 cases of abdominal aortic aneurysms (AAA), repectively. (Citation source http://buff.ly/1YxGpDA)
Read Article
Population-Based TB Risk and Prevention with RA and Biologics
In a retrospective cohort comparison study, 42,180 rheumatoid arthritis (RA) patients were compared 1:4 with 168,000 normal controls to examine the incidence of new tuberculosis in Taiwan. The RA population included those receiving csDMARDs (36,162), etanercept (3,577), adalimumab (1,67
Read Article
RheumNow Week in Review - 8 April 2016
Dr. Jack Cush reviews the rheumatology highlights from the news, media, and journals from this past week:
Read Article
Tofacitinib Efficacy Revealed in OPAL Study
Pfizer has issued a press release of its preliminary results from the OPAL study that examined the efficacy and safety of tofacitinib 5 mg and 10 mg twice daily (BID) in adults active psoriatic arthritis (PsA).
Read Article
Severe Psoriasis Associated with a Renal Disease Risk
There have been several reports of psoriasis being linked to chronic renal disease in the literature. Another population-based study has also found a link between severe psoriasis and kidney disease.
Read Article
Incidence of Psoriatic Arthritis Among Psoriasis Patients
Researchers at the University of Toronto have prospectively studied a cohort of 464 psoriasis patients without a diagnosis of arthritis and followed them over 8 years to estimate the incidence and frequency of psoriatic arthritis (PsA).
Read Article
1 in 2 Americans Have Musculoskeletal Conditions
A recent report from the United States Bone and Joint Initiative (USBJI) estimates that 126.6 million Americans (one in two adults) are affected by a musculoskeletal (MSK) condition; a number on par with the number of Americans living with a chronic lung or heart conditions.
Read Article
FDA Approves Taltz for Psoriasis
Tuesday the FDA approved the IL-17 inhibitor, Taltz (ixekizumab) for adults with moderate to severe plaque psoriasis. (Citation source http://buff.ly/1py10wd)
Read Article
